EJMK Ventures’s Bristol-Myers Squibb BMY Stock Holding History

EJMK Ventures’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,619	Closed	-$219K	–	165
2026 Q1	$219K	Sell	3,619 -993	-22%	-$57.9K	0.12%	155
2025 Q4	$249K	Buy	+4,612	New	+$222K	0.15%	153

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EJMK Ventures's BMY Position: Q2 2026 in Review

EJMK Ventures sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 3,619 shares — an estimated $219K sold.

EJMK Ventures first reported a position in BMY in Q4 2025 and held it in 2 quarters. The position peaked at $249K in Q4 2025. 2,502 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

EJMK Ventures reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
EJMK Ventures sold 3,619 Bristol-Myers Squibb shares in Q2 2026, an estimated $219K.
EJMK Ventures first reported a position in Bristol-Myers Squibb in Q4 2025 and held it in 2 quarters.
EJMK Ventures's Bristol-Myers Squibb position peaked at $249K in Q4 2025.
2,502 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on EJMK Ventures's 13F filing for Q2 2026, filed 6 Aug 2026.